Cullinan Therapeutics, Inc. Financials
CGEM
All currency values in $ millions unless otherwise noted
Scroll
| Income Statement | TTM | DEC 2025 | DEC 2024 ~1.4:1 split | DEC 2023 | DEC 2022 | DEC 2021 ~2.2:1 split |
|---|---|---|---|---|---|---|
| Revenues | ||||||
| Revenue | $0 | – | – | – | $0 | $19 |
| General & Administrative | $40 | $54 | $54 | $42 | $40 | $29 |
| Research & Development | $92 | $187 | $143 | $148 | $92 | $58 |
| Total Operating Expenses | $132 | $242 | $197 | $191 | $132 | $87 |
| Operating Income | $145 | -$242 | -$197 | -$191 | $145 | -$68 |
| Non-Operating | ||||||
| Net Interest Expense | $7 | $22 | $30 | $22 | $7 | $0 |
| Other Non-Operating Income (Expense) | $0 | -$0 | -$0 | $0 | $0 | -$0 |
| EBT (Earnings Before Tax) | $151 | -$220 | -$167 | -$169 | $151 | -$67 |
| Income Tax Expense | $42 | $0 | $0 | -$14 | $42 | $0 |
| Minority Interest | -$2 | $0 | -$0 | -$2 | -$2 | -$2 |
| Net Income | ||||||
| Net Income | $111 | -$220 | -$167 | -$153 | $111 | -$66 |
| Per Share Data | ||||||
| Revenue Per Share | $0.00 | – | – | – | $0.00 | $0.44 |
| EPS (Basic) | $2.46 | -$3.65 | -$2.86 | -$3.69 | $2.46 | -$1.52 |
| EPS (Diluted) | $2.38 | -$3.65 | -$2.86 | -$3.69 | $2.38 | -$1.52 |
| Weighted Avg Shares (Basic) | 45.2M | – | – | 41.5M | 45.2M | 43.1M |
| Weighted Avg Shares (Diluted) | 46.6M | – | – | 41.5M | 46.6M | 43.1M |
| Shares Outstanding | 46.6M | 60.2M | 58.5M | 41.5M | 46.6M | 43.1M |
Cullinan Therapeutics (CGEM) financials: revenue, profit and margins
Cullinan Therapeutics (CGEM) generated about n/a in revenue and -$203 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Cullinan Therapeutics profitable?+
Cullinan Therapeutics reported about -$203 million in net loss over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
SourceFinancial statements computed from the 10-Q filed 4 Nov 2026, covering the period ending 30 Sept 2026, as reported to the SEC. Data last refreshed 10 Nov 2026. How this is calculated.
Fiscal year ends Dec.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with CGEM
Held by ETFs
CGEM is in 40 US ETFs. The largest of them, with CGEM's weight in each:
Spot a number that looks wrong? Check it in CGEM's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing CGEM
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.